Disc Medicine (NASDAQ:IRON) CEO Sells $3,722,000.00 in Stock

Disc Medicine, Inc. (NASDAQ:IRON) CEO John Quisel sold 40,000 shares of the business’s stock in a transaction that occurred on Thursday, December 11th. The shares were sold at an average price of $93.05, for a total transaction of $3,722,000.00. Following the transaction, the chief executive officer directly owned 171,828 shares in the company, valued at $15,988,595.40. The trade was a 18.88% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink.

Disc Medicine Stock Up 0.2%

Shares of Disc Medicine stock traded up $0.15 on Monday, hitting $92.00. 792,687 shares of the company traded hands, compared to its average volume of 426,799. Disc Medicine, Inc. has a 12-month low of $30.82 and a 12-month high of $99.50. The company has a quick ratio of 23.45, a current ratio of 23.45 and a debt-to-equity ratio of 0.05. The company has a market cap of $3.47 billion, a PE ratio of -17.20 and a beta of 0.86. The company has a 50-day moving average price of $86.06 and a 200 day moving average price of $67.59.

Disc Medicine (NASDAQ:IRON) last posted its quarterly earnings results on Thursday, November 6th. The company reported ($1.77) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.48) by ($0.29). Sell-side analysts predict that Disc Medicine, Inc. will post -4.07 earnings per share for the current year.

Analyst Upgrades and Downgrades

Several equities analysts have commented on the stock. Cantor Fitzgerald increased their target price on shares of Disc Medicine from $132.00 to $153.00 and gave the stock an “overweight” rating in a research report on Friday, October 17th. Weiss Ratings restated a “sell (d-)” rating on shares of Disc Medicine in a research note on Wednesday, October 8th. Truist Financial lifted their target price on shares of Disc Medicine from $86.00 to $114.00 and gave the stock a “buy” rating in a report on Monday, November 10th. Wedbush boosted their price objective on Disc Medicine from $90.00 to $110.00 and gave the stock an “outperform” rating in a research report on Friday, October 17th. Finally, National Bankshares set a $153.00 price target on Disc Medicine in a research report on Friday, October 17th. One research analyst has rated the stock with a Strong Buy rating, nine have assigned a Buy rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus price target of $120.00.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently bought and sold shares of IRON. Wellington Management Group LLP increased its holdings in Disc Medicine by 67.9% in the 1st quarter. Wellington Management Group LLP now owns 2,343,499 shares of the company’s stock valued at $116,331,000 after buying an additional 948,094 shares during the period. RA Capital Management L.P. acquired a new position in Disc Medicine in the first quarter worth about $78,288,000. Vanguard Group Inc. lifted its stake in Disc Medicine by 3.7% during the third quarter. Vanguard Group Inc. now owns 1,448,059 shares of the company’s stock worth $95,688,000 after purchasing an additional 51,323 shares during the period. Siren L.L.C. acquired a new stake in Disc Medicine during the first quarter valued at approximately $53,207,000. Finally, JPMorgan Chase & Co. raised its holdings in shares of Disc Medicine by 11.1% in the 2nd quarter. JPMorgan Chase & Co. now owns 843,616 shares of the company’s stock worth $44,678,000 after buying an additional 84,278 shares in the last quarter. 83.70% of the stock is owned by institutional investors.

About Disc Medicine

Disc Medicine, Inc, together with its subsidiaries, a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases in the United States. The company has assembled a portfolio of clinical and preclinical product candidates that aim to modify fundamental biological pathways associated with the formation and function of red blood cells, primarily heme biosynthesis and iron homeostasis.